Impact of foot functionality in patients with systemic sclerosis: Cross-sectional study

被引:1
作者
-Luna, Esther Chicharro [1 ]
Gracia-Vesga, Miguel Angel [2 ]
Ramos-Petersen, Laura [3 ]
Gijon-Nogueron, Gabriel [4 ]
机构
[1] Univ Miguel Hernandez, Dept Behav Sci & Hlth, Nursing Area, Fac Med, Alacant, Spain
[2] Univ Miguel Hernandez, Occupat Therapy, Madrid, Spain
[3] Univ Malaga, Fac Hlth Sci, Dept Nursing & Podiatry, Malaga, Spain
[4] Univ Malaga, Fac Hlth Sci, Dept Nursing & Podiatry, IBIMA, Malaga, Spain
关键词
Sclerosis; Foot; Quality of life; Prevalence; Systemic sclerosis questionnaire; Foot function index; QUALITY-OF-LIFE; SCLERODERMA; INVOLVEMENT; VALIDATION;
D O I
10.1016/j.jtv.2024.03.004
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Progressive systemic sclerosis or systemic scleroderma (SS) is a chronic and rare autoimmune disease that mainly affects the skin and various internal organs. Raynaud's phenomenon and digital ulcers are some of the symptoms that affect the foot, causing a decrease in the quality of life of patients. The objective of this study is to determine the functionality of the feet in patients with SS and determine the impact on their daily lives. Methods: A sample of 165 patients (154 women, 11 men) diagnosed with SS with a mean age of 46.29 +/- 11.36 years and a mean body mass index (BMI) of 24.90 +/- 5.77 was recruited. Each participant completed the Foot Function Index (FFI) questionnaire and the Systemic Sclerosis Questionnaire (SySQ). A multivariate analysis was performed to determine which factors were related to a higher score in both questionnaires. Results: 32.1% of the participants (n = 53) had claw toe deformities, 79.4% (n = 131) Raynaud's disease and 20% (n = 33) a history of foot ulcers. 51.5% of the participants (n = 85) presented symptoms in their nails, the most frequent sign being thickening, hardening and yellow coloration. The final score of the FFI questionnaire was 3.51 +/- 2.41 (0-9.9), the pain subscale being the highest, with a score of 5.06 +/- 2.75, followed by foot disability (3.26 +/- 2.91) and difficulty performing activities (1.55 +/- 2.22). The final score of the SySQ questionnaire was 0.95 +/- 0.45 (0.18-2.45), and the subscales with the highest score were symptom frequency (1.30 +/- 0.47), symptom intensity (1.11 +/- 0.55), and general skill limitation (0.47 +/- 0.51). A high correlation was observed between the final FFI score and the final SySQ score (r = 0.712; p=<0.001). Also, between foot activity limitation and general skill limitation (r = 0.658; p=<0.001). A moderate correlation was observed between foot pain score and overall symptom intensity (r = 0.482; p=<0.001). Also, between foot disability and overall symptom frequency (r = 0.556; p=<0.001). The multivariate analysis (R2 0.51) showed that the final FFI score had a significant relationship with the final SySQ score (p < 0.001). No significant correlation was found between age (p = 0.15), gender (p = 0.49), BMI (p = 0.74) or time of diagnosis (p = 0.57) and FFI. Conclusion: SS is a disease that affects foot functionality in patients, with a greater impact on the pain scale. There is a correlation between the final FFI score and the final SySQ score, so improving foot functionality could help to improve the overall functionality of the patient with sclerosis.
引用
收藏
页码:202 / 207
页数:6
相关论文
共 37 条
  • [1] Pressure and pain In Systemic sclerosis/Scleroderma - an evaluation of a simple intervention (PISCES): randomised controlled trial protocol
    Alcacer-Pitarch, Begonya
    Buch, Maya H.
    Gray, Janine
    Denton, Christopher P.
    Herrick, Ariane
    Navarro-Coy, Nuria
    Collier, Howard
    Loughrey, Lorraine
    Pavitt, Sue
    Siddle, Heidi J.
    Wright, Jonathan
    Helliwell, Philip S.
    Emery, Paul
    Redmond, Anthony C.
    [J]. BMC MUSCULOSKELETAL DISORDERS, 2012, 13
  • [2] Quality of life in systemic sclerosis
    Almeida, Cristiana
    Almeida, Isabel
    Vasconcelos, Carlos
    [J]. AUTOIMMUNITY REVIEWS, 2015, 14 (12) : 1087 - 1096
  • [3] PRELIMINARY CRITERIA FOR THE CLASSIFICATION OF SYSTEMIC-SCLEROSIS (SCLERODERMA)
    不详
    [J]. ARTHRITIS AND RHEUMATISM, 1980, 23 (05): : 581 - 590
  • [4] Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis
    Bairkdar, Majd
    Rossides, Marios
    Westerlind, Helga
    Hesselstrand, Roger
    Arkema, Elizabeth, V
    Holmqvist, Marie
    [J]. RHEUMATOLOGY, 2021, 60 (07) : 3121 - 3133
  • [5] Belinda Basilio Fernandez, 2011, Rev espanola Podol, V22, P30
  • [6] Biomechanical podiatric evaluation in an Italian cohort of patients with systemic sclerosis: A pilot study
    Bongi, Susanna Maddali
    Ravenni, Giovanni
    Ciampi, Benedetta
    Del Rosso, Angela
    El Aoufy, Khadija
    [J]. EUROPEAN JOURNAL OF RHEUMATOLOGY, 2016, 3 (04) : 169 - 174
  • [7] A review of the foot function index and the foot function index - revised
    Budiman-Mak, Elly
    Conrad, Kendon J.
    Mazza, Jessica
    Stuck, Rodney M.
    [J]. JOURNAL OF FOOT AND ANKLE RESEARCH, 2013, 6
  • [8] Renal Involvement in Systemic Sclerosis: An Update
    Chrabaszcz, Magdalena
    Malyszko, Jolanta
    Sikora, Mariusz
    Alda-Malicka, Rosanna
    Stochmal, Anna
    Matuszkiewicz-Rowinska, Joanna
    Rudnicka, Lidia
    [J]. KIDNEY & BLOOD PRESSURE RESEARCH, 2020, 45 (04) : 532 - 548
  • [9] Peripheral neuropathy: a complication of systemic sclerosis
    Frech, Tracy M.
    Smith, Gordon
    Reily, Melissa
    Chamberlain, James
    Murtaugh, Maureen A.
    Penrod, Jason
    Battistone, Michael J.
    Stults, Barry M.
    [J]. CLINICAL RHEUMATOLOGY, 2013, 32 (06) : 885 - 888
  • [10] GIORDANO M, 1986, J RHEUMATOL, V13, P911